Brokerages Set GH Research PLC (NASDAQ:GHRS) Target Price at $40.38

Shares of GH Research PLC (NASDAQ:GHRS) have received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $40.3750.

Several analysts recently weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of GH Research in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Tuesday, April 21st. Cantor Fitzgerald boosted their price target on shares of GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Citizens Jmp dropped their price target on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, May 15th. Finally, Needham & Company LLC boosted their price target on shares of GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, March 6th.

GH Research Stock Performance

GH Research stock opened at $23.25 on Friday. GH Research has a fifty-two week low of $11.32 and a fifty-two week high of $25.94. The firm has a 50 day moving average price of $19.38 and a 200 day moving average price of $16.44. The company has a market capitalization of $1.60 billion, a PE ratio of -25.27 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). As a group, equities research analysts forecast that GH Research will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently modified their holdings of the business. Lynx1 Capital Management LP grew its stake in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after acquiring an additional 1,854,238 shares in the last quarter. RTW Investments LP grew its stake in shares of GH Research by 6.5% in the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock worth $75,359,000 after acquiring an additional 364,251 shares in the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of GH Research in the fourth quarter worth $22,860,000. Troluce Capital Advisors LLC grew its stake in shares of GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after acquiring an additional 617,260 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of GH Research by 324.1% in the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock worth $12,350,000 after acquiring an additional 659,957 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.